A brief intensive chemotherapy in T-prolymphocytic leukemia.
Billio
A
A
Pescosta
N
N
Rosanelli
C
C
Fabris
P
P
Coser
P
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy* / Q000628:therapy*; D015458:Leukemia, T-Cell / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D015649:Pentostatin / Q000008:administration & dosage; D011379:Prognosis; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D015649:Pentostatin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide; D008727:Methotrexate